Analyst Information

 

David Amsellem

Sr. Research Analyst

David Amsellem

David Amsellem is a managing director and senior research analyst at Piper Jaffray covering specialty pharmaceuticals. Prior to joining Piper Jaffray in 2008, Amsellem spent five years at Friedman Billings Ramsey, where he was a senior research analyst covering small- and mid-cap pharmaceuticals from 2006-2008 and a senior associate on the biotechnology equity research team from 2003-2006. Amsellem was recognized as the No. 1 ranked analyst in North America for accuracy of earnings estimates in the pharmaceuticals sector in the 2008 Financial Times/StarMine "Best Brokerage Analyst" survey. Amsellem has more than 10 years of Wall Street experience, including work in life sciences investment and merchant banking at Prudential Vector Healthcare. Amsellem graduated from Cornell University with a bachelor's degree in industrial relations.

Associates:

Michael Ingerman
Research Analyst
Sameer Kandola
Research Analyst
Universe Coverage:
Healthcare:   Specialty Pharmaceuticals
ACRXAcelRx Pharmaceuticals, Inc.
ADMSAdamas Pharmaceuticals, Inc.
AKRXAkorn, Inc.
AGNAllergan plc
AMPHAmphastar Pharmaceuticals, Inc.
ATRSAntares Pharma, Inc.
BDSIBioDelivery Sciences International, Inc.
COLLCollegium Pharmaceutical, Inc.
DEPODepomed, Inc.
EGRXEagle Pharmaceuticals Inc.
ENDPEndo International plc
HZNPHorizon Pharma plc
IPXLImpax Laboratories, Inc.
INSYInsys Therapeutics, Inc.
JAZZJazz Pharmaceuticals plc
MNKMallinckrodt
NOVNNovan, Inc.
PCRXPacira Pharmaceuticals, Inc.
REPHRecro Pharma, Inc.
RVNCRevance Therapeutics, Inc.
SHPGShire plc
SUPNSupernus Pharmaceuticals, Inc.
TEVATeva Pharmaceutical Industries Limited
VRXValeant Pharmaceuticals International